Drug Trial Radar · NCT05381948
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Jun 30, 2022
Primary completion
Nov 29, 2023
Study completion Apr 24, 2024
Sponsor
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
Conditions
- Wet Age-related Macular Degeneration
Interventions
EYP-1901Drug
Intravitreal Injection
Aflibercept 2mg/0.05mL Inj,OphDrug
Intravitreal Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32Time frame: Baseline (Day 1) and Weeks 28 and 32
Locations
67 sites in 1 country. Site status is shown where the registry gives one.
EyePoint Investigative Site
Phoenix, Arizona
EyePoint Investigative Site
Springdale, Arkansas
EyePoint Investigative Site
Beverly Hills, California
EyePoint Investigative Site
Campbell, California
EyePoint Investigative Site
Encino, California
EyePoint Investigative Site
Fullerton, California
EyePoint Investigative Site
Glendale, California
EyePoint Investigative Site
Huntington Beach, California
EyePoint Investigative Site
Irvine, California
EyePoint Investigative Site
Pasadena, California
EyePoint Investigative Site
Poway, California
EyePoint Investigative Site
Redlands, California
EyePoint Investigative Site
Sacramento, California
EyePoint Investigative Site
Walnut Creek, California
EyePoint Investigative Site
Lakewood, Colorado
EyePoint Investigative Site
Clearwater, Florida
EyePoint Investigative Site
Coral Springs, Florida
EyePoint Investigative Site
Lakeland, Florida
EyePoint Investigative Site
Melbourne, Florida
EyePoint Investigative Site
Miami, Florida
EyePoint Investigative Site
Pensacola, Florida
EyePoint Investigative Site
Sarasota, Florida
EyePoint Investigative Site
St. Petersburg, Florida
EyePoint Investigative Site
Tampa, Florida
EyePoint Investigative Site
Winter Haven, Florida
EyePoint Investigative Site
Marietta, Georgia
EyePoint Investigative Site
‘Aiea, Hawaii
EyePoint Investigative Site
Chicago, Illinois
EyePoint Investigative Site
Lemont, Illinois
EyePoint Investigative Site
Carmel, Indiana
EyePoint Investigative Site
West Des Moines, Iowa
EyePoint Investigative Site
Baltimore, Maryland
EyePoint Investigative Site
Hagerstown, Maryland
EyePoint Investigative Site
Owings Mills, Maryland
EyePoint Investigative Site
Boston, Massachusetts
EyePoint Investigative Site
Springfield, Massachusetts
EyePoint Investigative Site
Grand Rapids, Michigan
EyePoint Investigative Site
Saint Louis, Michigan
EyePoint Investigative Site
St Louis, Missouri
EyePoint Investigative Site
Reno, Nevada
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.